Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: An Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance

Schizophrenia is an unexplained, complex and serious mental illness. Blonanserin (BNS) is a new antipsychotic drug widely used in the treatment of schizophrenia. However, large-scale clinical studies have not been conducted in China. A multi-center, prospective, open-label, 12-week surveillance was...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Haishan, Wang, Xijin, Liu, Xuejun, Sang, Hong, Bo, Qijing, Yang, Xiaodong, Xun, Zhiyuan, Li, Keqing, Zhang, Ruiling, Sun, Meijuan, Cai, Duanfang, Deng, Huaili, Zhao, Guijun, Li, Juhong, Liu, Xianglai, Zhan, Guilai, Chen, Jindong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Psychiatry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9435526/
https://www.ncbi.nlm.nih.gov/pubmed/36061293
http://dx.doi.org/10.3389/fpsyt.2022.935769

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9435526/
https://www.ncbi.nlm.nih.gov/pubmed/36061293
http://dx.doi.org/10.3389/fpsyt.2022.935769

Ejemplares similares